Bolt Biotherapeutics
Husein Hadeiba is a Senior Scientist at Bolt Biotherapeutics, Inc. since May 2021, contributing to the development of innovative immunotherapies that harness antibody targeting alongside the innate and adaptive immune systems to combat cancer. Previously, Husein served as a Life Science Research Scientist and Principal Investigator at the Palo Alto Veterans Institute for Research from May 2009 to April 2021, where the focus was on advancing veteran and public health through research in Dendritic Cell biology. Husein's academic background includes postdoctoral studies in Immunology at Stanford University School of Medicine, a Ph.D. in Immunology from the University of California, San Francisco, and a dual degree in Molecular Cell Biology and Chemistry from the University of California, Berkeley, complemented by an International Baccalaureate Diploma from Vienna International School.
Bolt Biotherapeutics
7 followers
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.